A retrospective comparison of two drug regimens RHE2/RH10 and RHZ2/RH10 in the treatment of tuberculous mediastinal lymphadenopathy

British journal of diseases of the chest Pub Date : 1988-01-01 DOI:10.1016/0007-0971(88)90068-X

L.P. Ormerod

{"title":"A retrospective comparison of two drug regimens RHE2/RH10 and RHZ2/RH10 in the treatment of tuberculous mediastinal lymphadenopathy","authors":"L.P. Ormerod","doi":"10.1016/0007-0971(88)90068-X","DOIUrl":null,"url":null,"abstract":"<div>A retrospective radiographic comparison of two regimens, RHE2/RH10 (n=32) and RHZ2/RH10 (n=37), used in the treatment of tuberculous mediastinal lymphadenopathy is reported. The two groups did not differ in age, pretreatment or post-treatment values. The rate of improvement in serial radiographs was compared between the two groups, each patient acting as his own control. There was no difference in the incidence of initial gland enlargement at 1 month, but at 2 months RHZ2/RH10 had less enlargement (0.05>P>0.01). The rate of improvement was faster in the RHZ2/RH10 group from 2–7 months' treatment, being significantly better than RHE2/RH10 at 2 (P=0.003), 5 (0.01>P) and 7 months (0.02>P). Pyrazinamide (25–40 mg/kg) appears to be superior to ethambutol 15 mg/kg for the initial 2 months of treatment of tuberculous mediastinal lymphadenopathy. The findings may be applicable to peripheral tuberculous lymphadenopathy.</div>","PeriodicalId":75618,"journal":{"name":"British journal of diseases of the chest","volume":"82 ","pages":"Pages 274-281"},"PeriodicalIF":0.0000,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0007-0971(88)90068-X","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of diseases of the chest","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/000709718890068X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

A retrospective radiographic comparison of two regimens, RHE2/RH10 (n=32) and RHZ2/RH10 (n=37), used in the treatment of tuberculous mediastinal lymphadenopathy is reported. The two groups did not differ in age, pretreatment or post-treatment values. The rate of improvement in serial radiographs was compared between the two groups, each patient acting as his own control. There was no difference in the incidence of initial gland enlargement at 1 month, but at 2 months RHZ2/RH10 had less enlargement (0.05>P>0.01). The rate of improvement was faster in the RHZ2/RH10 group from 2–7 months' treatment, being significantly better than RHE2/RH10 at 2 (P=0.003), 5 (0.01>P) and 7 months (0.02>P). Pyrazinamide (25–40 mg/kg) appears to be superior to ethambutol 15 mg/kg for the initial 2 months of treatment of tuberculous mediastinal lymphadenopathy. The findings may be applicable to peripheral tuberculous lymphadenopathy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

两种药物方案RHE2/RH10和RHZ2/RH10治疗结核性纵隔淋巴结病的回顾性比较

回顾性比较两种方案，RHE2/RH10 (n=32)和RHZ2/RH10 (n=37)，用于治疗结核性纵隔淋巴结病报道。两组在年龄、治疗前后的价值上没有差异。比较两组患者连续x线片的改善率，每个患者作为自己的对照。两组在1个月时初始腺体肿大的发生率无差异，但在2个月时RHZ2/RH10的肿大较少(0.05>P>0.01)。治疗2 ~ 7个月时，RHZ2/RH10组改善速度较快，治疗2个月(P=0.003)、5个月(0.01>P)和7个月(0.02>P)时均显著优于RHE2/RH10组。在治疗结核性纵隔淋巴结病的最初2个月，吡嗪酰胺(25-40 mg/kg)似乎优于乙胺丁醇(15 mg/kg)。这些结果可能适用于周围性结核性淋巴结病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

British journal of diseases of the chest

自引率

0.00%

发文量

期刊最新文献

Chronic beryllium disease in identical twins. Induction of bronchial hyperresponsiveness following smoke inhalation injury. Progressive apical pleural fibrosis: a 'constrictive' ventilatory defect. Apical pulmonary fibrosis in psoriasis. Short course chemotherapy for lymph node tuberculosis: final report at 5 years. British Thoracic Society Research Committee.